VITATOX: Therapeutic Drug Monitoring (TDM) of Antibiotics by LC MS/MS

Importance of the Topic

Therapeutic drug monitoring (TDM) of antibiotics by LC-MS/MS addresses the critical need to optimize antibiotic therapy in critically ill patients. Variability in pharmacokinetics due to organ dysfunction, drug interactions and altered physiology leads to suboptimal dosing, contributing to treatment failure and antibiotic resistance. Implementing precise measurement of drug concentrations supports personalized dosing strategies and helps mitigate the rise of resistant pathogens.

Study Objectives and Overview

This presentation summarizes the development and application of an LC-MS/MS–based TDM platform for key antibiotics in intensive care settings. The goals were to:

• Establish a robust analytical method for quantifying a panel of 15 antibiotics and their internal standards.
• Evaluate the impact of concentration-guided dosing adjustments in an ICU pilot study.
• Demonstrate instrument compatibility and workflow integration using a commercial TDM kit.

Methodology and Instrumentation

The ClinMass® TDM Kit MS9700 was coupled to a Shimadzu Nexera LC system and SCIEX API TQ5500 mass spectrometer. Key steps included:

• Sample pretreatment by protein precipitation: 50 µl plasma mixed with 100 µl internal standard solution, centrifugation at 10 000 × g for 10 min.
• Dilution of 50 µl supernatant in 950 µl ultra-pure water prior to injection.
• LC separation with a total run time of 9.5 min and multiple reaction monitoring for each analyte.

Main Results and Discussion

In a one-year pilot study (November 2018–October 2019) at Chemnitz Hospital ICU, TDM data led to dose modifications in the majority of cases:

• Ceftazidime, meropenem and piperacillin dosing was frequently adjusted upward to reach therapeutic targets.
• Linezolid dosing was also fine-tuned based on measured concentrations.
• Staff feedback was very positive, prompting plans to expand the antibiotic panel further.

Pharmacokinetic/pharmacodynamic indices such as Cmax/MIC, AUC/MIC and % time above MIC guided dosing decisions and underscored the inadequacy of one-size-fits-all regimens in ICU patients.

Benefits and Practical Applications

Implementing LC-MS/MS–based TDM for antibiotics offers:

• Personalized dosing to maximize antimicrobial efficacy and minimize toxicity.
• Reduction of subtherapeutic exposure and prevention of resistance development.
• Streamlined workflow using commercial kits compatible with existing LC-MS/MS platforms.

Future Trends and Potential Applications

Emerging directions include:

• Expansion of analyte panels to cover additional critical antibiotics and metabolites.
• Automation of sample preparation and data processing for higher throughput.
• Integration of pharmacometric modeling and AI-driven dose calculators for real-time clinical decision support.

Conclusion

LC-MS/MS–based therapeutic drug monitoring of antibiotics represents a powerful tool for precision dosing in critically ill patients. The adoption of standardized TDM platforms can improve patient outcomes, limit resistance spread and provide a foundation for future automation and AI integration in clinical laboratories.